467 related articles for article (PubMed ID: 17087944)
1. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
Gonzalez-Rey E; Delgado M
Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic action of ghrelin in a mouse model of colitis.
Gonzalez-Rey E; Chorny A; Delgado M
Gastroenterology; 2006 May; 130(6):1707-20. PubMed ID: 16697735
[TBL] [Abstract][Full Text] [Related]
3. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.
González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
Gastroenterology; 2009 Mar; 136(3):978-89. PubMed ID: 19135996
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
5. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.
Zuo L; Huang Z; Dong L; Xu L; Zhu Y; Zeng K; Zhang C; Chen J; Zhang J
Gut; 2010 Apr; 59(4):470-9. PubMed ID: 19951904
[TBL] [Abstract][Full Text] [Related]
6. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4.
Arranz A; Juarranz Y; Leceta J; Gomariz RP; Martínez C
Peptides; 2008 Jun; 29(6):948-56. PubMed ID: 18359536
[TBL] [Abstract][Full Text] [Related]
7. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model.
Van Montfrans C; Rodriguez Pena MS; Pronk I; Ten Kate FJ; Te Velde AA; Van Deventer SJ
Gastroenterology; 2002 Dec; 123(6):1865-76. PubMed ID: 12454844
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis.
Gonzalez-Rey E; Fernandez-Martin A; Chorny A; Delgado M
Arthritis Rheum; 2006 Mar; 54(3):864-76. PubMed ID: 16508968
[TBL] [Abstract][Full Text] [Related]
9. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis.
Arranz A; Abad C; Juarranz Y; Torroba M; Rosignoli F; Leceta J; Gomariz RP; Martínez C
Ann N Y Acad Sci; 2006 Jul; 1070():129-34. PubMed ID: 16888154
[TBL] [Abstract][Full Text] [Related]
10. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
Gonzalez-Rey E; Delgado M
Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
[TBL] [Abstract][Full Text] [Related]
11. Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation.
Chorny A; Gonzalez-Rey E; Delgado M
Ann N Y Acad Sci; 2006 Nov; 1088():187-94. PubMed ID: 17192565
[TBL] [Abstract][Full Text] [Related]
12. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis.
Gonzalez-Rey E; Anderson P; González MA; Rico L; Büscher D; Delgado M
Gut; 2009 Jul; 58(7):929-39. PubMed ID: 19136511
[TBL] [Abstract][Full Text] [Related]
13. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells.
Gonzalez-Rey E; Chorny A; Varela N; O'Valle F; Delgado M
Arthritis Rheum; 2007 Feb; 56(2):531-43. PubMed ID: 17265488
[TBL] [Abstract][Full Text] [Related]
15. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
16. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
17. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide.
Pozo D; Anderson P; Gonzalez-Rey E
J Immunol; 2009 Oct; 183(7):4346-59. PubMed ID: 19734220
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease.
Gonzalez-Rey E; Fernandez-Martin A; Chorny A; Delgado M
Gut; 2006 Jun; 55(6):824-32. PubMed ID: 16401687
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.
González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
Arthritis Rheum; 2009 Apr; 60(4):1006-19. PubMed ID: 19333946
[TBL] [Abstract][Full Text] [Related]
20. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
